404 related articles for article (PubMed ID: 31650514)
21. Liraglutide vs. sitagliptin add-on to metformin treatment for type 2 diabetes mellitus: Short-term cost-per-controlled patient in Italy.
Ferrario MG; Lizán L; Montagnoli R; Ramírez de Arellano A
Prim Care Diabetes; 2016 Jun; 10(3):220-6. PubMed ID: 26546244
[TBL] [Abstract][Full Text] [Related]
22. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
[TBL] [Abstract][Full Text] [Related]
23. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B
Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation.
Meier JJ
Front Endocrinol (Lausanne); 2021; 12():645617. PubMed ID: 34248838
[TBL] [Abstract][Full Text] [Related]
25. Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin.
Wehler E; Lautsch D; Kowal S; Davies G; Briggs A; Li Q; Rajpathak S; Alsumali A
Pharmacoeconomics; 2021 Mar; 39(3):317-330. PubMed ID: 33150566
[TBL] [Abstract][Full Text] [Related]
26. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
Rosenstock J; Allison D; Birkenfeld AL; Blicher TM; Deenadayalan S; Jacobsen JB; Serusclat P; Violante R; Watada H; Davies M;
JAMA; 2019 Apr; 321(15):1466-1480. PubMed ID: 30903796
[TBL] [Abstract][Full Text] [Related]
27. Oral semaglutide for the treatment of type 2 diabetes.
Hedrington MS; Davis SN
Expert Opin Pharmacother; 2019 Feb; 20(2):133-141. PubMed ID: 30499733
[TBL] [Abstract][Full Text] [Related]
28. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
Yamada Y; Katagiri H; Hamamoto Y; Deenadayalan S; Navarria A; Nishijima K; Seino Y;
Lancet Diabetes Endocrinol; 2020 May; 8(5):377-391. PubMed ID: 32333875
[TBL] [Abstract][Full Text] [Related]
29. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo.
Lavernia F; Blonde L
Postgrad Med; 2020 Nov; 132(sup2):15-25. PubMed ID: 32815436
[TBL] [Abstract][Full Text] [Related]
30. Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis.
Igarashi A; Hunt B; Wilkinson L; Langer J; Pollock RF
Adv Ther; 2020 Oct; 37(10):4446-4457. PubMed ID: 32870471
[TBL] [Abstract][Full Text] [Related]
31. Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States.
Wilkinson L; Hunt B; Johansen P; Iyer NN; Dang-Tan T; Pollock RF
Diabetes Ther; 2018 Jun; 9(3):951-961. PubMed ID: 29557057
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA.
Hunt B; Mocarski M; Valentine WJ; Langer J
J Med Econ; 2017 Jul; 20(7):663-670. PubMed ID: 28294641
[TBL] [Abstract][Full Text] [Related]
33. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.
Rodbard HW; Rosenstock J; Canani LH; Deerochanawong C; Gumprecht J; Lindberg SØ; Lingvay I; Søndergaard AL; Treppendahl MB; Montanya E;
Diabetes Care; 2019 Dec; 42(12):2272-2281. PubMed ID: 31530666
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.
Yuan S; Wu Y
Front Public Health; 2023; 11():1201818. PubMed ID: 37744474
[TBL] [Abstract][Full Text] [Related]
35. A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.
Nauck MA; Petrie JR; Sesti G; Mannucci E; Courrèges JP; Lindegaard ML; Jensen CB; Atkin SL;
Diabetes Care; 2016 Feb; 39(2):231-41. PubMed ID: 26358288
[TBL] [Abstract][Full Text] [Related]
36. Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics.
Risebrough NA; Baker TM; Zhang L; Ali SN; Radin M; Dang-Tan T
Clin Ther; 2021 Nov; 43(11):1812-1826.e7. PubMed ID: 34728099
[TBL] [Abstract][Full Text] [Related]
37. Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial.
Buse JB; Bode BW; Mertens A; Cho YM; Christiansen E; Hertz CL; Nielsen MA; Pieber TR;
BMJ Open Diabetes Res Care; 2020 Dec; 8(2):. PubMed ID: 33318068
[TBL] [Abstract][Full Text] [Related]
38. Greater Combined Reductions of HbA
Dungan KM; Bardtrum L; Christiansen E; Eliasson J; Mellbin L; Woo VC; Vilsbøll T
Diabetes Ther; 2023 Aug; 14(8):1415-1425. PubMed ID: 37256503
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes.
Seino Y; Terauchi Y; Osonoi T; Yabe D; Abe N; Nishida T; Zacho J; Kaneko S
Diabetes Obes Metab; 2018 Feb; 20(2):378-388. PubMed ID: 28786547
[TBL] [Abstract][Full Text] [Related]
40. Evaluating the Cost of Bringing People with Type 2 Diabetes Mellitus to Multiple Targets of Treatment in Canada.
Skovgaard R; Jon Ploug U; Hunt B; Valentine WJ
Clin Ther; 2015 Aug; 37(8):1677-88. PubMed ID: 26186809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
